Edgewise reports Q3 net loss $12.9M; positive Phase 1 MAD data for EDG-5506

Edgewise Therapeutics, Inc.

Cash, cash equivalents and marketable securities of $290M as of Sept 30, 2021.
R&D expenses $9.9M (Q3 2021) vs $3.2M (Q3 2020), increase due to Phase 1 trial and headcount.
Net loss $12.9M ($0.26/share) compared to $3.6M in Q3 2020.
Positive EDG-5506 Phase 1 MAD topline: well tolerated, target engagement, no effect on voluntary strength or cardiac myosin.
First BMD patients dosed in Phase 1b; Phase 2 trials in BMD and DMD expected to start in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.